text:
Drug information provided by: IBM Micromedex
Diclofenac and misoprostol combination is used to relieve symptoms of arthritis (eg, osteoarthritis or rheumatoid arthritis) in patients who may develop stomach ulcers from taking nonsteroidal anti-inflammatory drugs (NSAIDs).
Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID), used to relieve symptoms of arthritis such as inflammation, swelling, stiffness, and joint pain. Misoprostol is used to decrease the chance of having stomach and intestinal ulcers.
This medicine is available only with your doctor's prescription.
This product is available in the following dosage forms:
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:
Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Appropriate studies have not been performed on the relationship of age to the effects of diclofenac and misoprostol combination in the pediatric population. Safety and efficacy have not been established.
Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of diclofenac and misoprostol combination in the elderly. However, elderly patients may be more sensitive to the effects of diclofenac and misoprostol combination than younger adults, and are more likely to have age-related kidney problems, which may require caution and an adjustment in the dose for patients receiving this medicine.
There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.
Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking this medicine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.
Using this medicine with any of the following medicines is not recommended. Your doctor may decide not to treat you with this medication or change some of the other medicines you take.
Using this medicine with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.
Using this medicine with any of the following medicines may cause an increased risk of certain side effects, but using both drugs may be the best treatment for you. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.
Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.
The presence of other medical problems may affect the use of this medicine. Make sure you tell your doctor if you have any other medical problems, especially:
For safe and effective use of this medicine, do not take more of it, do not take it more often, and do not take it for a longer time than ordered by your doctor. Taking too much of this medicine may increase the chance of unwanted effects. Do not change the dose or stop using this medicine without checking first with your doctor.
This medicine should come with a Medication Guide and a patient information leaflet. Read and follow these instructions carefully. Ask your doctor if you have any questions.
Do not take diclofenac and misoprostol combination with magnesium-containing antacids. Antacids may be taken with diclofenac and misoprostol combination, if needed, to help relieve stomach pain, unless you are otherwise directed by your doctor. However, do not take magnesium-containing antacids, since they may cause diarrhea or worsen the diarrhea that is sometimes caused by this medicine.
Do not give this medicine to another person.
Diclofenac and misoprostol combination should be taken with meals. Swallow the tablets whole. Do not chew, crush, or dissolve it.
The dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.
The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.
If you miss a dose of this medicine, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses.
Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.
Keep out of the reach of children.
Do not keep outdated medicine or medicine no longer needed.
Ask your healthcare professional how you should dispose of any medicine you do not use.
It is very important that your doctor check your progress at regular visits. This will allow your doctor to see if the medicine is working properly and to decide if you should continue to take it. Blood and urine tests may be needed to check for unwanted effects.
Using this medicine while you are pregnant can cause very serious birth defects. Use two forms of effective birth control to keep from getting pregnant while you are using this medicine and after treatment ends. The most effective forms of birth control are hormone birth control pills, patches, shots, vaginal rings, or implants, an IUD, or a vasectomy (for men). One of these forms of birth control should be combined with a condom, a diaphragm, or a cervical cap. Also, you must have a negative pregnancy test within 2 weeks before you will be allowed to take this medicine. If you think you have become pregnant while using this medicine, stop taking this medicine and tell your doctor right away.
This medicine may raise your risk of having a heart attack or stroke. This is more likely in people who already have heart disease. People who use this medicine for a long time might also have a higher risk.
This medicine may cause bleeding in your stomach or intestines. These problems can happen without warning signs. This is more likely if you have had a stomach ulcer in the past, if you smoke or drink alcohol regularly, are over 60 years of age, are in poor health, or are using certain medicines (such as a steroid medicine or a blood thinner).
Check with your doctor right away if you have any symptoms of liver problems including dark-colored urine or pale stools, nausea, vomiting, loss of appetite, pain in your upper stomach, or yellowing of your skin or the whites of your eyes.
This medicine may cause a serious type of allergic reaction called anaphylaxis. Anaphylaxis can be life-threatening and requires immediate medical attention. Call your doctor right away if you have a rash, itching, hoarseness, trouble breathing, trouble swallowing, or any swelling of your hands, face, or mouth while you are using this medicine.
Serious skin reactions can occur during treatment with this medicine. Check with your doctor right away if you have any of the following symptoms while taking this medicine: blistering, peeling, loosening of the skin, chills, cough, diarrhea, fever, itching, joint or muscle pain, red skin lesions, sore throat, sores ulcers, white spots in the mouth or on the lips, or unusual tiredness or weakness.
Call your doctor right away if you have confusion, drowsiness, fever, general feeling of illness, headache, loss of appetite, nausea, stiff neck or back, or vomiting. These could be symptoms of aseptic meningitis.
Tell your doctor if you have unexplained weight gain or edema (fluid retention or body swelling) with this medicine.
This medicine may cause diarrhea in some people. The diarrhea will usually disappear within a few days as your body adjusts to the medicine. However, check with your doctor if the diarrhea is severe or does not stop after a week.
Stomach problems may be more likely to occur if you drink alcoholic beverages while being treated with this medicine. Therefore, do not regularly drink alcoholic beverages while taking this medicine, unless otherwise directed by your doctor.
Taking nonsteroidal anti-inflammatory drugs (eg, acetaminophen, aspirin or other salicylates, or ketorolac, Toradol®) together with this medicine on a regular basis may increase the chance of unwanted effects. The risk will depend on how much of each medicine you take everyday, and on how long you take the medicine together. If your doctor directs you to take these medicines together on a regular basis, follow his or her directions carefully. However, do not take acetaminophen or aspirin or other salicylates together with this medicine for more than a few days, and do not take any ketorolac (eg, Toradol®) while you are taking this medicine, unless your doctor has directed you to do so and is following your progress.
Do not take other medicines unless they have been discussed with your doctor. This includes prescription or nonprescription (over-the-counter [OTC]) medicines and herbal or vitamin supplements.
Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur:
Get emergency help immediately if any of the following symptoms of overdose occur:
Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.
Portions of this document last updated: Oct. 01, 2018
Original article: https://www.mayoclinic.org/drugs-supplements/diclofenac-and-misoprostol-oral-route/proper-use/drg-20061810
Copyright © 2019 IBM Watson Health. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes.
Any use of this site constitutes your agreement to the Terms and Conditions and Privacy Policy linked below.
Mayo Clinic is a nonprofit organization and proceeds from Web advertising help support our mission. Mayo Clinic does not endorse any of the third party products and services advertised.
A single copy of these materials may be reprinted for noncommercial personal use only. "Mayo," "Mayo Clinic," "MayoClinic.org," "Mayo Clinic Healthy Living," and the triple-shield Mayo Clinic logo are trademarks of Mayo Foundation for Medical Education and Research.


text:
|Attention: DocWiki has reached EOL and will be decommissioned January 25, 2019.
General: Irrevocable damage to node in a cluster
From DocWiki
Irrevocable damage to node in a cluster
|Problem Summary
|A node in the cluster has been damaged irrevocably and needs to be reinstalled from scratch.
|Error Message
|The installation proceeds normally, but the post-install setup wizard does not come up as it normally does the first time you enter the administration application after a fresh install. You are therefore not given the opportunity to select whether this is a Primary, Secondary or Expansion node, and the MediaSense services do not start up.
|Possible Cause
|The MediaSense cluster believes the setup wizard has already been executed for this node.
|Recommended Action
|Contact Cisco TAC to reset the setup wizard. Then restart the node and sign in to the administration application again.
|All releases.
|Associated CDETS #

subset: commoncrawl


text:
Finding a Safe and Effective Dose of Linagliptin in Pediatric Patients With Type 2 Diabetes
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
|ClinicalTrials.gov Identifier: NCT01342484
Recruitment Status : Completed
First Posted : April 27, 2011
Results First Posted : September 15, 2016
Last Update Posted : September 15, 2016
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
The main objective of this study is to identify the dose of linagliptin in paediatric patients.
Other efficacy objectives include the comparison of the lowering effect of linagliptin low dose, high dose and placebo on the fasting plasma glucose (FPG) observed after 12 wk of treatment.
Furthermore, the study will investigate the pharmacokinetics (PK), the pharmacodynamics (PD) and the PK/PD relationship of linagliptin in the paediatric population.
|Condition or disease
|Diabetes Mellitus, Type 2
|Drug: placebo Drug: BI1356 low dose Drug: BI1356 high dose
|Phase 2
|Study Type :
|Interventional (Clinical Trial)
|Actual Enrollment :
|40 participants
|Intervention Model:
|Parallel Assignment
|Primary Purpose:
|Official Title:
|A Randomised, Double-blind, Placebo-controlled, Parallel Group Dose-finding Study of Linagliptin (1 and 5 mg Administered Orally Once Daily) Over 12 Weeks in Children and Adolescents, From 10 to 17 Years of Age, With Type 2 Diabetes Mellitus
|Study Start Date :
|April 2011
|Actual Primary Completion Date :
|February 2016
|Actual Study Completion Date :
|February 2016
Experimental: linagliptin low dose
linagliptin low dose for children once daily
Drug: BI1356 low dose
comparison of different dosages of drug (low vs high) vs placebo
Experimental: linagliptin high dose
linagliptin high dose for children once daily
Drug: BI1356 high dose
comparison of different dosages of drug (low vs high) vs placebo
Placebo Comparator: placebo
matching placebo for each linagliptin dose once daily
Drug: placebo
comparison of different dosages of drug (low vs high) vs placebo
- Change From Baseline in Glycosylated Haemoglobin (HbA1c) (%) After 12 Weeks of Treatment [ Time Frame: Baseline and 12 weeks ]Change from baseline in Glycosylated haemoglobin (HbA1c) [%] after 12 weeks of treatment with double-blind trial medication. Baseline was defined as the last observation before the first intake of any double-blind randomised trial medication. The number of participants analysed displays the number of participants with available data at the timepoint of interest.
- Dipeptidyl-peptidase-4 (DPP-4) Inhibition (%) at Trough at Steady State [ Time Frame: Baseline and 4 weeks or 8 weeks or 12 weeks ]DPP-4 inhibition (%) at trough at steady state is the relative change between the measurement of DPP-4 activity taken 0.5 hours before dosing at baseline and the first available on-treatment measurement of DPP-4 activity taken 0.5 hour before dosing at week 4, 8 or 12: DPP-4 inhibition (%) = 100 - (DPP-4 activity at week X / DPP-4 activity at baseline) x 100.
- Change From Baseline in Fasting Plasma Glucose (FPG) After 12 Weeks of Treatment [ Time Frame: Baseline and 12 weeks ]Change from baseline in FPG (mmol/L) after 12 weeks of treatment with double-blind trial medication. The number of participants analysed displays the number of participants with available data at the timepoint of interest.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:
|10 Years to 17 Years (Child)
|Sexes Eligible for Study:
|Accepts Healthy Volunteers:
Inclusion criteria:
- Paediatric patients (children and adolescents), aged 10 to 17 years with documented diagnosis of type 2 diabetes mellitus
- Insufficient glycaemic control (i.e. an HbA1c > 6.5% and <= 10.5%) despite treatment with diet and exercise and/or metformin (>= 1000 mg per day (or the maximum tolerated dose) at a stable dose or dosing frequency for 8 weeks prior to randomisation) and/or concomitant stable basal insulin (total daily dose must be <= 0.5U/kg with less than 10% of weekly dose change for 12 weeks prior to randomisation)
- Negative for islet cell antigen (ICA) auto-antibodies and glutamic acid decarboxylase (GAD) auto-antibodies
- C-peptide levels (serum) >= 1.5 ng/ml (at 90 min following a Boost challenge)
Exclusion criteria:
- History of acute metabolic decompensation, such as diabetic ketoacidosis, within 3 months
- Current short-acting insulin or having received short-acting insulin for more than 3 days within 1 month prior to randomisation
- Treatment with weight reduction medications (including anti-obesity treatments)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01342484
|United States, Texas
|1218.56.01006 Boehringer Ingelheim Investigational Site
|San Antonio, Texas, United States
|United States, Virginia
|1218.56.01004 Boehringer Ingelheim Investigational Site
|Norfolk, Virginia, United States
|Canada, Quebec
|1218.56.11001 Boehringer Ingelheim Investigational Site
|Montreal, Quebec, Canada
|1218.56.33003 Boehringer Ingelheim Investigational Site
|Fort de France cedex, France
|1218.56.33006 Boehringer Ingelheim Investigational Site
|Rouen, France
|1218.56.50202 Boehringer Ingelheim Investigational Site
|Guatemala, Guatemala
|1218.56.50203 Boehringer Ingelheim Investigational Site
|Guatemala, Guatemala
|1218.56.39005 Boehringer Ingelheim Investigational Site
|Firenze, Italy
|Korea, Republic of
|1218.56.82005 Boehringer Ingelheim Investigational Site
|Busan, Korea, Republic of
|1218.56.82001 Boehringer Ingelheim Investigational Site
|Seoul, Korea, Republic of
|1218.56.82002 Boehringer Ingelheim Investigational Site
|Seoul, Korea, Republic of
|1218.56.82003 Boehringer Ingelheim Investigational Site
|Suwon, Korea, Republic of
|1218.56.52008 Boehringer Ingelheim Investigational Site
|Chihuahua, Mexico
|1218.56.52002 Boehringer Ingelheim Investigational Site
|Guadalajara, Mexico
|1218.56.52001 Boehringer Ingelheim Investigational Site
|León, Mexico
|1218.56.52003 Boehringer Ingelheim Investigational Site
|Monterrey, Mexico
|1218.56.52004 Boehringer Ingelheim Investigational Site
|Oaxaca, Mexico
|1218.56.48002 Boehringer Ingelheim Investigational Site
|Gdansk, Poland
|1218.56.48001 Boehringer Ingelheim Investigational Site
|Gliwice, Poland
|1218.56.48004 Boehringer Ingelheim Investigational Site
|Warszawa, Poland
|1218.56.48003 Boehringer Ingelheim Investigational Site
|Wroclaw, Poland
|Russian Federation
|1218.56.70001 Boehringer Ingelheim Investigational Site
|Moscow, Russian Federation
|1218.56.70003 Boehringer Ingelheim Investigational Site
|Saratov, Russian Federation
|1218.56.70004 Boehringer Ingelheim Investigational Site
|Ufa, Russian Federation
|1218.56.70006 Boehringer Ingelheim Investigational Site
|Yekaterinburg, Russian Federation
|Study Chair:
|Boehringer Ingelheim
|Boehringer Ingelheim
|Responsible Party:
|Boehringer Ingelheim
|ClinicalTrials.gov Identifier:
|NCT01342484 History of Changes
|Other Study ID Numbers:
2009-017004-91 ( EudraCT Number: EudraCT )
|First Posted:
|April 27, 2011 Key Record Dates
|Results First Posted:
|September 15, 2016
|Last Update Posted:
|September 15, 2016
|Last Verified:
|July 2016
Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Hypoglycemic Agents
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists
Dipeptidyl-Peptidase IV Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action


text:
10 Denim Shorts With The Editor Stamp of Approval
Full disclosure: I'm not actually much of a shorts person. But that's not to say I don't love a good pair of denim cutoffs when the temperature rises. In fact, my default summer outfit is slouchy, perfectly worn-in shorts paired with a blue button-down and Greek sandals--an easy-chic formula for the season. Since no stylish wardrobe is complete without a couple pairs of denim shorts in the mix, I've gathered 10 of my favorite options to help you shop the look now!
Slouchy Boy Fit Shredded Low-Rise Denim Shorts ($187)
Thanks to a slightly longer length and light wash, these shorts are a great throwback to the '90s, which is a trend I'm loving right now.
Mid Rise Destroyed Shorts ($195)
These shorts look great on every type of figure, as they're just slouchy enough and not too short.
Le Cutoff Denim Shorts ($159, 416.861.9111) in Paradis Green
If you're not a fan of rips and holes, but still want to get that worn-in look, you'll love these shorts by FRAME Denim. The khaki color plus the cool of the subtly frayed hem equals perfection.
Slouch Cut Off Shorts ($265)
I could live in these denim shorts all summer long; the slouchy fit and distressed detailing give them plenty of cool-girl appeal. And while it may seem like a big investment for a pair of shorts, I can promise they will play part in your off-duty wardrobe until the leaves turn.
Dinky Embroidered-Star Shorts ($241)
Every time I look at these coquettish shorts, I think of the south of France. Style them with a bright red halter top and patent leather sandals for your next barbecue.
Echo Park Shorts ($139)
Of all the printed shorts this season, I have my heart set on Paige's Echo Park Shorts in White Rose. They're fun, feminine, and flirtatious--three important "F"s for the season.
Empire Denim Shorts ($139)
Color is never a bad thing, especially when it comes to warm-weather denim. A shot of coral looks great with a crisp white button-down and penny loafers.
Rolled Vintage Inspired Shorts ($98) in Melodie
Every girl needs a pair of cuffed denim shorts in a classic medium wash. They are a bit more polished than your casual cutoff, which means you can easily dress them up or down with a switch of a shoe.
Lola Shorts ($98) in Milk
DL1961's white shorts will take you stylishly through the sunny months. While I would team these with a pair of Ancient Greek Sandals and a Breton-stripe shirt, you can also brighten them up with a neon tank.
Studded Shorts ($108)
I see a touch of the Wild West in this embellished pair, so style them with pieces that subtly nod to the trend, like low-heel ankle boots and a chambray button-down.


text:
Farm shows, at their heart, are about connecting products with customers. Even a major event like Agritechnica at its core makes those connections - sometimes it's a company with a distributor who will eventually reach the customer. Traveling through the halls on Day 2 of their fantastic journey, photographer Mark Moore and Willie Vogt, editorial director, pushed through more halls looking for the new, the interesting and more.
What they found ranges from new seat technology aimed at improved operator comfort to monitoring technology that can be expanded to keep track of a range of inputs from grain quality to fuel management (in time). There's even a new tire concept that mates the idea of tire and track into one unique unit that offers a range of features.
One thing Agritechnica draws is the prototype. Yesterday's gallery carried a few prototype machines on display, and there were more to be found on Day 2 as well. The Fieldball concept brings a whole new method forward for defeating farm compaction, and there's no axle involved. And companies are working on new ways to use apps and tablets to better set up equipment.
So read on, check out the photos and learn more about the products and information we found at the show.
Don't miss our coverage at farmindustrynews.com/agritechnica.


text:
2014 Audi SQ5 First Test
The 2014 Audi SQ5 stands out as an overtly sporting entry in a segment largely characterized by anonymous, sanitized luxury.
Introduced in 2008, the Audi Q5 was yet another entry in the premium crossover segment taking advantage of meteoric global demand for the breed. and while it had the understatedly handsome looks and upscalefeel as is expected of an Audi product, nothing about it was a segment-busting game-changer. With its 354-hp supercharged V-6, and attention-grabbing exhaust snarl, the SQ5 definitely stands out as an overtly sporting entry in a segment largely characterized by anonymous, sanitized luxury.
Visually, differences between the standard Q5 and SQ5 are fairly subtle. A lower-rear-bumper accent piece, with quad exhaust tips, set it apart from lesser Q5 models, while beefy 15-inch front and 13-inch rear vented disc brakes show that this crossover is built for more than just groceries and soccer practice. Inside, the differences are a little more noticeable, the most apparent being Audi's signature flat-bottom steering wheel signifying its deliberately high-performance models.
Firing up the SQ5's supercharged 3.0-liter direct-injected V-6 still doesn't give much clue to the driving experience in store, with the civilized muted purr expected of an upscale luxury vehicle. The less overtly-sporting Q5 3.0T shares a lower-boost version of the same engine. Don't ask why Audi still insists on denoting its supercharged engines with a "T." At part throttle, the SQ5 behaves as you'd expect of a $50,000+ luxury crossover, with responsive acceleration, and a subtly sporty,-but-not-obnoxious exhaust burble. But if you kick down the throttle in anger, the SQ5 responds in-kind with a ferociously raw exhaust note accompanying the brisk acceleration.
The 0-60 sprint is dispatched in just 4.8 seconds, with a 13.5-second quarter-mile time -- Legitimately quick in anyone's book, and especially so for an SUV. At first, we thought the SQ5 was equipped with a double-clutch transmission, since shifts were so lightning-quick, a characteristic we've come to expect from Audi's S tronic dual-clutch boxes. But double-checking the spec sheet, we came to realize the SQ5 has a conventional torque-converter eight-speed automatic. The SQ5's smooth low-speed crawling behavior demonstrated one of the advantages of a traditional automatic over a dual-clutch, which can sometimes lurch a bit in low-speed stop-and-go driving.
But don't think a traditional slushbox kills all the fun. In sport mode and using the paddle shifters on the steering wheel, the SQ5 felt right at home on the backroad twisties. Since we live in Southern California, one of the more densely-populated metropolitan areas in the U.S., we found ourselves having to pull over to let the traffic open up to fully enjoy the SQ5's canyon-carving talents. The SQ5's pizza-pan-sized brakes aren't just for looks, either, with ample fade resistance, and the ability to bring this 4400-pouns SUV to a halt from 60 mph in just 104 feet.
So the SQ5's enthusiast chops have been firmly established, but how does it fare in the area of value? Like most high-performance German vehicles, that judgment is subjective, and the SQ5 is right on the edge of being considered a deal versus being overpriced. Total price on our Prestige model was $64,770, including destination. Certainly not the most egregious asking price we've seen for an upscale SUV. But if you can skip the Prestige package, the Estoril Blue paint, and black wood/aluminum wood interior inlays and other accoutrements, you could drive off an Audi lot for just $52,795. At that price, the SQ5 strikes us as a compelling buy, although we don't think a Navigation system or HD radio should be optional at that price, which are available as a $3400 option package, bringing the total to $56,195. That's right on the edge of what we'd subjectively say is "worth it."
But if you value performance just as much or more than utility in your SUV, and are willing to pay a premium for it, we can confidently say the Audi SQ5 delivers the goods, with an endearingly mischievous personality that will egg you on when the mood strikes.
|2014 Audi SQ5
|Front-engine, AWD, 5-pass, 4-door SUV
|3.0L/354 hp/347 lb-ft supercharged DOHC 24-valve V-6
|8-speed automatic
|4401 lb (54/46%)
|110.5 in
|LENGTH x WIDTH x HEIGHT
|183.0 x 75.2 x 65.3 in
|4.8 sec
|13.5 sec @ 102.2 mph
|104 ft
|0.86 g (avg)
|25.9 sec @ 0.71 g (avg)
|16/23 mpg
|211/147 kW-hrs/100 miles
|1.05 lb/mile


text:
your bag
Your bag is empty.
Sorry, this product has sold out!
If you would like ARCHFASHION to try to and find it for you complete the form below.
Baby blue lace with baby blue underlay high neck with knife pleat skirt body-con style invisible back zip closure exclusive to xenia boutique 65% cotton 35% polyester lined,non sheer length of size 6/xmall (shoulder to hem): 86cm model wears size 6/xsmall model height: 180cm without heels


text:
Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
|ClinicalTrials.gov Identifier: NCT01169337
Recruitment Status : Active, not recruiting
First Posted : July 26, 2010
Last Update Posted : January 7, 2019
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
|Condition or disease
|Light Chain Deposition Disease Smoldering Plasma Cell Myeloma
|Other: Clinical Observation Drug: Lenalidomide Other: Quality-of-Life Assessment
|Phase 3
Show Detailed Description
|Study Type :
|Interventional (Clinical Trial)
|Estimated Enrollment :
|180 participants
|Intervention Model:
|Parallel Assignment
|None (Open Label)
|Primary Purpose:
|Official Title:
|Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
|Actual Study Start Date :
|October 5, 2010
|Estimated Primary Completion Date :
|March 15, 2020
Experimental: Arm A (lenalidomide)
Patients receive lenalidomide PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Drug: Lenalidomide
Given PO
Other Names:
Other: Quality-of-Life Assessment
Ancillary studies
Other Name: Quality of Life Assessment
Active Comparator: Arm B (observation)
Patients undergo observation until progression to symptomatic myeloma.
Other: Clinical Observation
Undergo observation
Other Name: observation
Other: Quality-of-Life Assessment
Ancillary studies
Other Name: Quality of Life Assessment
- Incidence of grade 3 or higher toxicities based on Cancer Therapy Evaluation Program-Adverse Event Reporting System expedited reporting (Phase II) [ Time Frame: Up to 6 months ]
- PFS (Phase III) [ Time Frame: Up to 10 years ]PFS in each of the arms will be estimated using the method of Kaplan and Meier. PFS between the two arms will be compared using a stratified log-rank test. Cox proportional hazards model will be used to assess PFS outcome in multiple regression analyses of established prognostic factors.
- Response rate (complete and partial response) [ Time Frame: Up to 10 years ]Calculated with a 95% confidence interval.
- Duration of response [ Time Frame: Up to 10 years ]Estimated using the Kaplan-Meier method.
- Incidence of adverse events graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (CTCAE version 5.0 beginning April 1, 2018) [ Time Frame: Up to 10 years ]Adverse events will be monitored on all patients and summarized by arm. The difference in rates of all grade 3 or higher toxicities will be evaluated for all randomized patients using the Fisher's Exact test.
- Overall survival (OS) [ Time Frame: Up to 10 years ]OS in each of the arms estimated using the method of Kaplan and Meier. OS between the two arms will be compared using stratified log-rank test. Cox proportional hazards model will be used to estimate hazard rate between arms.
- Mean change of the FACT-FWB+PWB score [ Time Frame: Baseline to up to 24 months ]A two-sided t-test will be used.
- Change in FACT-FWB+PWB mean scores between patients that experience disease progression (PD) and patients who do not experience PD [ Time Frame: Baseline to up to 48 months ]Assessed using mixed effects model.
- Sensitivity for patients that did experience PD during the interval with respect to change in QOL in QOL status since last QOL assessment [ Time Frame: Up to 48 months ]
- Reliability of PACT-FWB+PWB [ Time Frame: Up to 10 years ]Descriptive statistics will be provided and Chronbach's alpha will be calculated to assess reliability.
- Reliability of MMS [ Time Frame: Up to 10 years ]Descriptive statistics will be provided and Chronbach's alpha will be calculated to assess reliability.
- Differences in the MMS between the two arms [ Time Frame: At 24 months ]
- Validity of FACT-PWB+FWB [ Time Frame: Up to 10 years ]Patients will be segmented into clinical groups such as ECOG performance status 0-1 vs 2 that are expected to have significantly different scores and these relationships will be analyzed with 1-way multivariate analysis of variance (MANOVA). When MANOVA is significant then a univariate analysis of variance is done on each dependent variable.
- Validity of MMS [ Time Frame: Up to 10 years ]Patients will be segmented into clinical groups such as ECOG performance status 0-1 vs 2 that are expected to have significantly different scores and these relationships will be analyzed with 1-way MANOVA. When MANOVA is significant then a univariate analysis of variance is done on each dependent variable.
- Change in gene expression profiling [ Time Frame: Baseline to up to 10 years ]Exploratory analyses will be performed to examine the underlying distributions using box plots, density plots, scatter plots, etc. Differential expression analysis of the two groups (baseline vs. off-study) will be performed.
- Change in immune expression [ Time Frame: Baseline to up to 10 years ]Changes in immune expression will be evaluated only by descriptive statistics for hypothesis generation.
- Presence of focal lesions on baseline MRI [ Time Frame: Baseline ]The data about the presence of focal lesions on baseline MRI studies will be analyzed and correlated with clinical outcome. The difference in response rates will be analyzed using the Fisher's exact test assuming a target overall response rate of 30% and 5% level of significance.
- Prevalence of cytogenetic abnormalities [ Time Frame: Up to 10 years ]There will be 80% power with the logrank test to detect a hazard ratio comparing high-risk vs. standard-risk cytogenetic groups.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:
|18 Years and older (Adult, Older Adult)
|Sexes Eligible for Study:
|Accepts Healthy Volunteers:
Inclusion Criteria:
Patients must be diagnosed with asymptomatic high-risk smoldering multiple myeloma (SMM) within the past 60 months, as confirmed by both of the following:
- Bone marrow plasmacytosis with >= 10% plasma cells or sheets of plasma cells at any time before initiating study treatment, including a marrow which must be obtained by bone marrow aspiration and/or biopsy within 4 weeks prior to randomization
- Abnormal serum free light chain ratio (< 0.26 or > 1.65) by serum free light chain (FLC) assay; FLC assay must be performed within 28 days of randomization
- Patients must have measurable levels of monoclonal protein (M-protein): >= 1g/dL on serum protein electrophoresis or >= 200 mg of monoclonal protein on a 24 hour urine protein electrophoresis which must be obtained within 4 weeks prior to randomization
- Patients must have no lytic lesions on skeletal surveys and no hypercalcemia (i.e., >= 11 mg/dL)
- Hemoglobin >= 11 g/dL within four weeks prior to randomization
- Platelet count >= 100,000/mm^3 within four weeks prior to randomization
- Absolute neutrophil count (ANC) >= 1,500/mm^3 within four weeks prior to randomization
- Calculated creatinine clearance >= 30 mL/min within four weeks prior to randomization
- Bilirubin =< 1.5 mg/dL within four weeks prior to randomization
- Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) and serum glutamic oxaloacetic transaminase (SGPT) (aspartate aminotransferase [AST]) =< 2.5 times upper limit of normal within four weeks prior to randomization
- No prior or concurrent systemic or radiation therapy for the treatment of myeloma
- Concurrent use of bisphosphonates is not permitted; however, prior bisphosphonates or once-a-year intravenous bisphosphonate given for the treatment of osteoporosis is permitted
- Prior or concurrent use of erythropoietin is disallowed
- Prior glucocorticosteroid therapy for the treatment of multiple myeloma is not permitted
- Prior systemic glucocorticosteroid use for the treatment of non-malignant disorders is permitted; concurrent use after registration on the study should be restricted to the equivalent of prednisone 10 mg per day
- Prior or concurrent topical or localized glucocorticosteroid therapy to treat non-malignant comorbid disorders is permitted
- Patients must not have active, uncontrolled seizure disorder; patients must have had no seizures in the last 6 months
- Patients must not have uncontrolled intercurrent illness including uncontrolled hypertension, symptomatic congestive heart failure, unstable angina, uncontrolled cardiac arrhythmia, uncontrolled psychiatric illness or social situation that would limit compliance with the study, or a prior history of Stevens Johnson syndrome
- Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2
- Patients must not have baseline bone lesions or plasmacytomas
- Patients with monoclonal gammopathy of undetermined significance are not eligible
- Patients must not have grade 2 or higher peripheral neuropathy
- Patients must not have active, uncontrolled infection
- Patients may have a history of current or previous deep vein thrombosis or pulmonary embolism but are required to take some form of anti-coagulation as prophylaxis if they are not currently on full-dose anticoagulation
- Patients should not have New York Heart Association classification III or IV heart failure
- Patients with a history of prior malignancy are eligible provided they were treated with curative intent and have been free of disease for the time period considered appropriate for cure of the specific cancer; for most diseases this time frame is 5 years
- Patients should not be felt to have an immediate need for chemotherapy
- Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 10 - 14 days prior to and again within 24 hours of starting cycle 1 of lenalidomide and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide; FCBP must also agree to ongoing pregnancy testing; men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy; a FCBP is a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months); all patients must be counseled by a trained counselor every 28 days about pregnancy precautions and risks of fetal exposure
Human immunodeficiency virus (HIV) infection is not excluded; HIV+ patients must meet the following criteria:
- Cluster of differentiation (CD)4 cell count >= 350/mm^3
- No history of acquired immune deficiency syndrome (AIDS)-related illness
- Not currently prescribed zidovudine or stavudine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01169337
Show 618 Study Locations
|Principal Investigator:
|Sagar Lonial
|ECOG-ACRIN Cancer Research Group
|Responsible Party:
|National Cancer Institute (NCI)
|ClinicalTrials.gov Identifier:
|NCT01169337 History of Changes
|Other Study ID Numbers:
NCI-2011-02057 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
E3A06 ( Other Identifier: ECOG-ACRIN Cancer Research Group )
E3A06 ( Other Identifier: CTEP )
U10CA180820 ( U.S. NIH Grant/Contract )
U10CA021115 ( U.S. NIH Grant/Contract )
U24CA196172 ( U.S. NIH Grant/Contract )
|First Posted:
|July 26, 2010 Key Record Dates
|Last Update Posted:
|January 7, 2019
|Last Verified:
|July 2018
Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Immunologic Factors
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Antineoplastic Agents
Immunosuppressive Agents
Leprostatic Agents
Anti-Bacterial Agents
Anti-Infective Agents


text:
Reine Claude (Green Gage Plum) and vanilla jam
So, what do you do when you find a big box of the fabulous Green Gage Plums at the farmers market? Make jam, of course! Green Gage plums are called Reine Claude in French. These particular ones, with greenish-yellow skin and occasional red blush, are called Reine Claude Crottée I believe. No matter the name, Reine Claudes are particular great for jams and preserves. In the raw state, they are fragrant, sweet and so juicy as to be almost watery. When cooked down into compote or jam, the liquid concentrates and the flavor intensifies. There's also a good amount of acidity to balance the sweetness and plenty natural pectin in the skin so there's no need to add any more.
I first bought about three pounds of these gorgeous fruit from Patrick at Thomas farm. Took them home, and made a quick batch of compote with a couple of vanilla beans, which is a recipe more or less cribbed from Christine Ferber's Mes Confitures book. They turned out so amazingly delicious that I ran back to the market just before it's closed and bought ten more pounds. Yeah. Ten. I went plum mad.
The first batch I made was so simple. Just the plums, sugar, a vanilla pod or two and a little lemon juice. The plan is to make a yummy jam to be the filler for my pop tarts. Even if you've never made jam before, or just the mere mention of preserving and canning is enough to send you to hide behind the sofa, you really should try it. If you find the whole preserving business too daunting, just make a small batch of jam and keep it in the fridge. It's really easy to do and you can have the flavor and consistency just the way you like it.
Green Gage plum and vanilla Jam
2lb (about 1kg) Green Gage Plums
1lb (about 500g) sugar
juice from 1 lemon
2 vanilla beans
Cut the plums into big chunks into a large, non-reactive pot (like a Le Creuset), discard the pits. Add the sugar and the lemon juice. Stir well to combine. Cut a round piece of parchment paper the size of the diameter of the pot, and place it on top of the fruits. Let sit for about an hour.
Cut two vanilla beans lengthwise, scrape the inside of the pods to get to all the seeds. Scrape the pods and all the seeds into the pot with the fruits. Place the pot over the stove and bring to a boil over medium heat. Gently stir to make sure all the sugar is melted. Bring the heat down to a simmer, and continue to cook, stirring occasionally, until it reduces at least by half or until it reaches the thickness you like.
These plums have so much pectin in the skin that you don't need to add any extra to get it to gel. To test to see if the jam is ready, take a small amount of jam on the tip of a spoon, and drop it on a small plate and spread it a little. If the jam is ready, it should gel up nicely when it cools down. If it's still a little runny, you might want to continue cooking for just a bit longer.
It really is that simple. If you're like me, you can just put the jam in a large jar and put it in the fridge (discard the vanilla pods first, by the way). It will be eaten up soon enough. If you want to keep it longer, then get a bunch of little jam jars and follow the manufacturer's instructions on how to fill and seal the jars so that they are shelf-stable.


text:
(NewsUSA) – If you owed taxes last year or received a refund that was larger than expected, it may be a good idea to adjust the amount you're having withheld from your paycheck. As the end of the year looms, there's still time to talk to a licensed tax specialist about your withholding and other possibilities for easing your tax burden.
Here are some tips for last-minute tax savings from America's tax experts, the National Association of Enrolled Agents — a group of licensed tax practitioners who focus solely on taxation year-round.
* Increase or max out retirement contributions. Contribute more to your 401(k) to reduce your taxable income and your tax bill.
* Gift-giving is another year-end tool. For 2013, the annual gift tax exclusion is $14,000 ($28,000 for married couples making split-gifts). Qualified individuals can also make a gift to charity from IRA funds, but only through the end of the year.
* If you can itemize deductions, giving to charity may also reduce your tax bill. In addition to contributions made by cash, check or credit card, the crisp fall air may provide the energy to clean house looking for items in good condition that can be donated to a qualified charitable organization. Remember to make a list of the items and determine their fair market value. Clip the list to the receipt from the organization, and keep it with your tax documents for your records.
* Sometimes, a major life change is thrown your way, and you might not think of it as a tax deduction. If you found yourself looking for a new job, then agency fees, resumé expenses, career counseling costs and travel related to the job search may be deductible even if the job search was unsuccessful.
* On January 1, 2013, the new 3.8 percent net investment income (NII) surtax took effect. The surtax, which was passed by Congress to help fund health care reform, is imposed on the net investment income of higher-income individuals, estates and trusts that exceeds certain thresholds. Generally, the surtax applies to passive income but can also hit capital gains from the disposition of property. New strategies should be considered to minimize, if possible, the surtax. There is also a new 0.9 percent Additional Medicare Tax that reaches higher income individuals.
* Watch the news! Keep an eye on what's happening with taxes as the year draws to a close. If Congress keeps to past practice, late tax legislation might mean a delay to the start of the tax-filing season. If any adjustments in your plan need to be made, you won't be too late.
Get more tips and find an enrolled agent at www.naea.org.
This article is copyright free. You are free to use it on a blog, website, in a newspaper, or newsletter.
To re-post this, copy the content above, or HTML on the right, and paste onto your site.


text:
In discussing members of Congress, a careful look at their voting record should be noted. Contrary to whatever some of the television ads say, the candidate might not vote the way you care about. So it is important to check the politician's voting record with any groups that you are affiliated with. By calling their office it might be possible to talk to the representative themselves. They are generally glad to hear from the constituency and will explain their opinion to you. A more immediate answer can come from the Internet.
One of the most disturbing things about the lawmakers is the fact there isn't a minimum attendance requirement for these lawmakers. Considering that they earn $174,000 per year, you would expect them to be at their job every day. When they are in their office or on the floor they average about 28 hours per week. Most congressmen fly home every weekend but when at home some spend time with their constituents or attending political functions. Therefore there is no voting on bills on Mondays or Fridays and so the work week actually starts on Tuesdays after 6:30 p.m. The amount of working days however is key as it appears they are always off or at recess. A study was made on the 2010 Congress and the final tally indicated the total of workdays was 137 out of 365. If you factor in weekends and holidays, there are 260 days available for work. Therefore the Congress worked only 53 percent of a work year. Based on these figures, they receive $1,270 per day and in the event of an 8-hour day, it is $157 per hour. There have been cases where legislators have been known to miss as many as 60 percent of the votes they should have cast.
In election years, they will finish business in mid-September and adjourn until January. When they return they will then take a 3-week recess. So all major bills that will determine our financial situation for the next few years will be left unsolved until after the election. It seems to be a "cop out" for those who are coming up for re-election to not let their constituents know how they would have performed their legal duties.
In the Senate, in order to get a recorded vote is to actually have a roll call vote where it is known as the Yeas and Nays. The clerk calls all senators in alphabetical order and even though they are supposed to vote from their seats, many prefer to go to the roster to explain their position and perhaps to influence others. After a 30-minute session, the voting is closed and ballots are counted.
In the House of Representatives however, the "Yeas" and "Nays" recorded vote may be demanded under certain rules if there is a quorum present. When certain bills are being discussed, such as a general appropriations bill, a bill raising taxes or for the annual budget the votes will be recorded. A teller vote may be used by using a green card for "Aye", red for "Nay" and orange for "Present" (or abstaining). The preferred method would be using a plastic voting card which is also a photo ID placed into terminals in the backs of seats and casting the vote by pushing a button. As usual, the colors are similar to the Senate. The vote is shown on a display board above the Speaker's chair next to the member's name while displaying the totals on the side panels.
Observation: The manner in which it is given is worth more than the gift.


text:
Uluru, Uluru-Kata Tjuta National Park, NT
World Heritage-listed Uluru is one of Australia's most iconic symbols. Located in the heart of Uluru-Kata Tjuta National Park in Australia's Red Centre, Uluru is an ancient landscape, rich in Australian indigenous culture and spirituality. There are many ways to experience the majesty of Uluru and the beauty of this unique desert landscape. Take a walk with an Aboriginal guide and learn about ancient traditions and stories from the Dreamtime. See it from the skies by helicopter or hot air balloon. Ride across the ochre coloured desert on a Harley Davidson motorcycle or on the back of a camel.


text:
Choose Your Support
Customer Support
Questions about your order or about the website?
Choose from the following:
Local Support
Questions about a product or a service you see on our site?
Choose from the following:
Categories: Forceps, Pliers, Hemostats & Removers : Forceps
Extracting Forceps – # 3F Woodward, Universal, Horn Beak, Straight Handle - J&J Instruments Inc.
These extracting forceps are made of 420 stainless steel and used to extract lower 1st and 2nd molars from the alveolar bone.
- Universal, horn beak and straight handle
- All edges beveled and smoothed
- Interior of box lock is finished and polished


text:
Message Board
Cathy Kelly Message Board
Talk about the novels, new and used books that Kelly has written!
Author Kelly's Book Reviews
Just Between Us
Hugh and Rose are have been married for 40 years and on the day of their anniversary party Rose walks out of the marriage because she finally faced the truth about Hugh having affairs over the years. Stella, the oldest child is divorced with a young daughter of her own. She may have a brilliant career as a lawyer but is afraid at her age, she may never find true love. In walks Nick, the man she could be happy forever with except he is also divorced wi...
Someone Like You
Plume, May 2002, 14.00, 472 pp. ISBN: 0452283388 Thirty-seven year old American Hannah Campbell is not really enjoying her trysts with her younger perfect male specimen though the muscle bound stud helps her somewhat forget her former spouse whose off traipsing somewhere like the Amazon. Though Jeff Williams would have been the leading model for an Ancient Rome statue, a bored Hannah leaves him to visit Egypt. At the Pyramids, Hannah meets a fo...


text:
T&B Rigid Fittings BlueKote Universal Conduit Elbow (LU) Form 8 replaces four conduit body configurations. The conduit elbow enables fiber-optic cable to be run in a ¾-in. system, instead of a 2-in. system, and still maintain the cable bend radius. An angled covered port facilitates wire pulling and uses standard covers. Because the product is UL-listed as an enclosure, splices are permitted inside of it. In addition, it is rated for 40% wire fill, avoiding the need to de-rate the system.
Thomas & Betts
For more information, visit www.tnb.com.
Hide comments


text:
- This event has passed.
Worship 2nd Service
November 25, 2018 @ 11:00 am - 12:00 pm
|Recurring Event (See all)
Every Sunday
Event Navigation
Sundays 11am in the Worship Center
Children's Church meets in the Children's Theater at the front of the campus.
Nursery – Pre-K meet downstairs Building B
Some adult classes meet during this time while others meet during the other worship service time.


text:
British Academy: Small Research Grants
The British Academy, established by Royal Charter in 1902, is the national academy for the humanities and the social sciences. It is an independent, self-governing fellowship of more than 800 scholars, elected for distinction and achievement in one or more branches of the academic disciplines that make up the humanities and social sciences.
The Academy supports postdoctoral research in the humanities and social sciences through its research grants schemes, promoting relations between researchers in the UK and overseas, and recognising distinction in scholarship. It runs a varied programme of events, and has an active publications programme. It also engages with and advises on major policy issues in the higher education sector.
Deadlines: 15 October, 15 January and 15 April each year.
Grants are available to support primary research in the humanities and social sciences. Applications will not be considered for less than £500. The maximum grant is £7,500 over two years. Applications for collaborative or individual projects are equally welcome under this scheme.
Closing dates are 15 October, 15 January and 15 April. Results will be issued approximately three months after the closing date. Web www.britac.ac.uk/funding/guide/srg.html∞
| CBA, St Mary's House, 66 Bootham, York YO30 7BZ.
tel: +(44) (0)1904 671417 | fax: +(44) (0)1904 671384 | email:


text:
|2013-01-02, 07:28
|Link #39065
I am no one
Join Date: Apr 2010
Location: Inside your head
I always think during the tournament, Uchigane limiter is removed for that very reason. It's only weakness in that state, is VERY limited arsenal, AFAIK.
Yeah, Houki suck, but being suck due to a perfectly justified reason.
|2013-01-03, 09:43
|Link #39073
I am no one
Join Date: Apr 2010
Location: Inside your head
The I.S. arena seems to be capable of forming semi-solid objects using barrier manipulation, emulating floating decoy to slice shouldn't be that hard, I dunno about moving object though.
|2013-01-03, 09:50
|Link #39075
That one guy
Join Date: Nov 2011
@zero: that makes sense. Did the anime indicate that they could make the barrier simulation replicate physics as well? Material density, mass, bouncing, trajectory, etc.?
@stratos: Generally it's good to keep some suspense by with holding the name. But sometimes you should just spit it out. It's mostly more on timing really.
|2013-01-03, 09:51
|Link #39076
I am no one
Join Date: Apr 2010
Location: Inside your head
@ Stratos
Either choice is fine I think
@ Demi
I dunno, but I figure for training purposes, the decoy are kept fragile to conserve power. Besides, projecting a MOVING barrier would be very complex process even for I.S. core, much less for mere arena.
I think the better approach would be object forming randomly and the trainee is given a time limit to destroy them
|2013-01-03, 09:57
|Link #39079
That one guy
Join Date: Nov 2011
@eras: Representative candidates are given special training, but noobs aren't.
@zero: dang... the idea was to cut the tennis balls in two, not just hit them. Hitting them indicates you can reach them but not necessarily a solid strike. Not even leaving a deep impression or getting the ball stuck onto the blade is passable. It has to be a cut. So if the training decoys are that fragile... well... hmmm...
|fanfic ideas, fanfiction, ff.net, harem, is fanfic, warning fanfic spoilers, wincest
|Thread Tools


text:
Came across an interesting story on the BBC today: http://www.bbc.co.uk/news/technology-23898080
"Patent trolls take out generalised patents, often on widely available technology, and then demand money from companies who use or offer it. Shops and restaurants have been targeted for displaying QR codes and online store-locators...."
After which I tried to find out what the QR Code issue was. Which led me to this blog post: http://www.paperspecs.com/30344/beware-the-qr-code-patent-trap/
According to that, "if your QR code sends people to a URL shortener, Neomedia claims you're infringing their patents."
(Namely, US Patent 6,199,048 and US Patent 8,131,597)
Does anyone happen to know whether there are equivalent or similar patents covering the UK, or is this purely an American issue? And are there any other patent issues around QR codes, or are only URL shortened URLs a problem?
(I don't think we use QR codes a lot on our campus, but this story baffled me...)
Views: 2061
With the usual caveats about not constituting legal advice, etc., I feel confident about using QR codes here in Canada without any particular concern over legal issues. With regards to this specific lawsuit you could always link to the full URL, and then present the shortened URL in text on the same print piece or signage. That would avoid the QR-to-short-URL issue.
I keep hoping QR will begin to be built into camera apps by default and then begin to take off, because I consider it a nifty 'gateway drug' to full augmented reality. However, so far, no traction on that...
I do notice that QR is now being used in WeChat to add new users to group conversations, so that might spread it a bit more widely. However I think the uptake on QR has always been greater in Asia than in North America, so it may remain a technology that never does quite reach critical mass here.
What do you think, do any of you have situations where QR works well for you on campus?
To be honest, I have yet to see a QR Code which has enhanced my life, as a user. It's easier to find bad examples of QR codes than good ones. (A railway station in Bristol replaced all the timetables on platforms with QR Codes, so you could only find out what trains were running if you had a smartphone and mobile broadband and the patience to leaf through a PDF on a phone. A department in the University printed QR codes in a brochure. The QR codes were the links to the PDF of the very brochure itself.)
I could imagine QR codes having some degree of usefulness, if you can use them to "check in" to something on Facebook or some other geosocial network, or to "review / read reviews of" restaurants on Tripadvisor. I could imagine QR codes being handy for booking attendance at something in advance ("Here next week: Careers talk" > QR Code to book on eventbrite / add to your own calendar). I could imagine that it might one day be good for libraries: scan a QR code on a physical copy to loan out a digital copy of something (ebook, ejournal, movie) and then access the digital copy at home but leave the physical copy in the library.
But in truth, I haven't seen any of those uses of QR codes so far. Instead, what I tend to see is information that used to be available disappearing, replaced with a QR code, or people hoping for user curiosity, placing QR codes with little or no context somewhere as guerilla advertising tool (only no one ever scans them, as who knows where they might lead...)
Quite simply, so far I haven't seen a use of a QR code that was genuinely rewarding for the users.
Very good points, and in general I agree.
Here at Brescia we identified a 'test use case' for QR: When students pile off the bus from main campus, they all have smartphone in hand, so we created a simple 'Daily Brescia' web page for announcements such as events and class cancellations. (http://www.brescia.uwo.ca/daily/) which is accessible by URL and QR. Uptake has been low, but I suspect it may pick up a bit when we start adding the daily lunch specials... food motivates! :)
The future Higher Ed uses that I can see for QR, and for locational augmented reality (AR) in general, are mostly in extending signage and location information with timely overlays of additional data or functionality. I see it as a fundamentally informational technology, rather than as one suited to the kind of marketing applications that are common so far.
Having said that, I think QR is a transitional technology on the road to AR that has probably not caught enough momentum to survive. I doubt that it will be a part of the digital media mix 5 years from now, unless new applications like the WeChat example give it new life.
© 2019 Created by Mark Greenfield. Powered by


text:
The buzz used to be that Lincoln had Marfan Syndrome. Then it was chronic depression. Now cardiologist John Sotos is telling us that Lincoln had something called multiple endocrine neoplasia, type 2B, a rare genetic disorder that leads to cancer.
Sotos is the same guy who diagnosed President Taft with obstructive sleep apnea. Apneos, a company that specializes in sleep disorders, assures us that "[w]ith the possible exception of Lincoln, no man has faced greater challenges as President than William Howard Taft. " Apparently the War of 1812, the Great Depression, and the Cuban Missile Crisis were minor nuisances compared to a tendency to doze off in public. But I digress.
Anyway, the Grand Army of the Republic Civil War Museum and Library in Philadelphia has some fabric from a pillowcase stained with Lincoln's blood. Sotos is trying to talk the museum into allowing a DNA test on the artifact to determine if his cancer syndrome theory is true.
I don't find any of this medical speculation to be particularly significant, and I've said so. What we're dealing with here is a very specific question. Was Lincoln sick, or wasn't he? That's the scope of this investigation, and when you get right down to it, it's rather limited.
But you'd never believe it by listening to Sotos, who can make a pitch like a seasoned Hollywood pro. From the above-linked news item:
The disorder leads to thyroid or adrenal cancer, and Sotos cites Lincoln's weight loss in office and an appearance of ill health during his final months. He said a finding that Lincoln had the genetic disorder and probably cancer could shed light on his presidency.…
If Lincoln was seriously ill and knew it, Sotos said, that might explain stories of his premonitions about death.
'I don't think it was mysticism, I think that was him knowing what his body was telling him,' Sotos said. 'Then if you're a historian, I think you have to say … how does that affect how you run the war, your clemency toward soldiers who may have deserted their post, the way you reconcile with the South?'
A website on his research offers more breathlessly-reported implications. You want to unlock the mystery of Lincoln's awkwardness around women? How about his indifference to his own personal safety? Multiple endocrine neoplasia might just be good for whatever ails you.
What's next? Could a nasty arthritic cramp account for the brevity of the Gettysburg Address? Could a flare-up of irritable bowel syndrome explain that spat with Meade after Gettysburg?
The fact of the matter is that by raising all these speculative implications, Sotos is writing a lot of checks, and I doubt he'll be able to cash them by drawing on mutliple endocrine neoplasia. He likes history, and he wants to make the ever-elusive Original Contribution to historical understanding. But his approach is too reductionist to accomplish everything he hopes for it.
In fact, his medical training may be a real liability when it comes to historical investigation. From a purely medical standpoint, a human being is a skin sack full of physical components that interact in various ways. When the machine breaks down, it's a matter of finding the glitch and correcting it. It seems that Sotos has approached not only Lincoln, but the study history as a whole, in this same manner.
You've got a singular historical figure in extraordinary circumstances, and Sotos approaches this situation in the same way he would approach a patient with chest pains. He finds some physical ailment that accounts for all the symptoms, and he runs with the ball. That's great if you're dealing with a human body with a given complaint, but if you're dealing with a human being in a set of historical/political/cultural circumstances, it's just not the right tool for the job.
Lincoln was fatalistic during his entire life, and given his Calvinist upbringing, that shouldn't be surprising. His conciliationist approach to Reconstruction didn't emerge out of thin air during his last months in office. His leniency toward condemned soldiers is perfectly consistent with his behavior as a boy, when he regretted shooting a wild turkey and could never again bring himself to fire at anything bigger, and lectured his friends when they caught and tormented animals.
If Sotos wants to explain Lincoln, then he's going to have to do history. And that means poring over manuscripts, muddling through clunky monographs, chasing down references, and staring at the screen of a microfilm reader for hours on end. That's where you'll find out what these people were doing, what made them tick, and what roles they fulfilled in their own societies. No magic bullets. No sudden "eureka!" moment in the laboratory. It's not any museum's red tape that's stopping him; it's his attempt to diagnose history with one fell swoop.
"I'm not interested in how Lincoln might have died. I'm interested in how he might have lived," he told the reporter in the story linked above. If that's true, then he needs to stop bringing a knife to a gunfight.
(Lincoln photo via Wikimedia Commons)


text:
Turning 103, Los Angeles man gets city street sign
LOS ANGELES (AP) — It's not every day that someone turns 103, even in a city as big as Los Angeles.
So to recognize the 103rd birthday of Leon Saliba, city officials made an official street sign bearing his name.
The Los Angeles Times reported (http://lat.ms/1djK2EU ) that Saliba was supposed to travel to 103rd street in the city's Watts neighborhood for a ceremony Thursday, but warm weather and bad traffic gave his daughter pause.
So the city councilman representing Saliba's neighborhood in the San Fernando Valley instead brought the street sign to his home.
The sign has Saliba's name printed in capital letters below "103rd Street."
Saliba was all smiles, quipping "I can't take a sign I shouldn't have."
This is not the first year that his city councilman, Tom LaBonge, has honored Saliba.
Two years ago, LaBonge, an avid photographer, made a picture of Saliba standing near a sign for the U.S. 101 freeway.
Last year, LaBonge photographed him standing outside Los Angeles fire station 102.
"I don't know what I'm going to do for 104," LaBonge said. "But I've got a year to figure it out."
Information from: Los Angeles Times, http://www.latimes.com
Sorry we are not currently accepting comments on this article.


text:
[ Contact Information | Support | Feedback | SSH Home Page | SSH Products ]
Copyright © 2007 SSH Communications Security Corp.
Highlights from the SSH.COM blog:
Cryptomining with the SSH protocol: what big enterprises need to know about itCryptomining malware is primarily thought of as targeting desktops and laptops and is used to hijack system resources to mine cryptocurrency.
Read more
SLAM the door shut on traditional privileged access managementDid you know that something as trivial-sounding as granting access for your developers or third parties to a product development environment can throw a gorilla-sized monkey wrench into your operations and productivity?
Read more
We broke the IT security perimeterEveryone understands the concept of a security perimeter. You only gain access if you are identified and authorized to do so.
Read more


text:
|2011 has been a wonderful year in its own way, but I for one can't wait to begin 2012. I have so many ideas brewing for French Charmed, and I just have a feeling that this year is going to be spectacular all around! I usually end up making seemingly impossible resolutions (finally get organized! learn how to swim! become a world-famous jazz singer!), but this year, I think I'll keep it simple: I'm going to try and recognize a beautiful moment about each and every day, no matter how small and simple that moment might be. I truly do believe that if we live in the present, enjoy the blessings that are right in front of us and be thankful for what we already have, we will be happier people all around. So that's what I plan to do! What are some of your New Year resolutions? I hope one of them is to swing by and see some of the gorgeous new products we have in the French Charmed boutique! There's no better way to start a new year than treating yourself to something special, right? Love and hugs to you all!
Photo credits from top to bottom: elizabethannedesigns.com, favim.com, mallofamerica.com, corksandcaftans.com, citified.blogspot.com, Life Magazine, lipseyeshair.tumblr.com, curioussofa.com


text:
Lady Bisons close out War Eagle Classic
Feb. 21, 2006
The Lady Bisons closed out platy in the War Eagle Classic Sunday afternoon, lsoing 10-0 to the host Auburn Tigers in Auburn, Ala.
Lipscomb first baseman Heather Collins was named to the All-Tournament Team.
The Lady Bisons managed only one hit in the game. Shortstop Kate Richards singled to left center to start off the third inning.
Sara Meek started for the Lady Bisons. She pitched three innings, allowing five hits and six runs, five earned. Allison Tyree pitched one inning, giving up four hits and four runs, all earned. She struck out one batter.


text:
Message Board
Peg Kehret Message Board
Talk about the novels, new and used books that Kehret has written!
Author Kehret's Book Reviews
Blizzard Disaster
Tom and Betsy are working together again on another school project. They decide to use a time traveling machine, an invention of Tom's late grandfather, and they go back the past. They go back to a blizzard that happened near the Rocky Mountains years ago which killed many people. They get stuck in the snow with a little girl,and can't escape with the time machine because it is frozen. It looks like time is running out again, only this time, will they...
Small Steps
In the book Small Steps a thirteen year old girl, Peg, gets polio, and has to go to a hospital called Unniversity Hospital for the first half of her recovering and for the second part she goes to Sheltering Arms. At Sheltering Arm Peg meets her new roomates Alice, Renee, Dorothy, and Shirley were she makes friendships she doesn't want to leave. Peg has to go through stages like getting hot packs and then using hot baths instead, or how she got a bed,...
The Volcano Disaster
Volcano Disaster is about a boy and a girl named Tom and Betsy. They are working together on a school project about the explosion of Mount St. Helens in 1940. Tom finds an invention of his dead grandfather, a backpack that is a time machine! Betsy and Tom put themselves back into time to Mt. St. Helens right before the explosion. Everything is going great and it looks like they are going to have a best project in the class. But they have one slight pr...


text:
Central Electric and Appliance CO - Teaneck, NJ - Phone: (201) 836-2522
Key Properties LLC - Teaneck, NJ - Phone: (201) 836-6100
Norwood Electric Inc - Teaneck, NJ - Phone: (201) 836-1510
Nunery Le Roy & Sons - Teaneck, NJ - Phone: (201) 837-0612
Southside Electric Inc - Teaneck, NJ - Phone: (201) 530-1200
An electrician in Teaneck is a tradesman specializing in electrical wiring of buildings, stationary machines and related equipment. Electricians may be employed in the installation of new electrical components or the maintenance and repair of existing electrical infrastructure. Electricians may also specialize in wiring ships, airplanes, and other mobile platforms. Electricians are typically not allowed to perform work for the public unless under the employment of an electrical contractor. The job of an electrician is a regulated trade for safety reasons due to the many hazards of working with electricity, requiring testing, registration, or licensing. Licensing of electricians is controlled through government and/or professional societies in Teaneck.


text:
Obama Planning Inaugural Prayer Service
President Barack Obama is planning an inaugural prayer service at the National Cathedral the morning after he takes the oath of office.
An inaugural service has been a tradition for most modern presidencies. Obama plans to hold his on Jan. 22 at 10:30 a.m. That's according to people involved in the planning speaking on a condition of anonymity without authorization to discuss the event ahead of its official announcement.
Obama begins his second term at noon on Sunday, Jan. 20, and is planning a private swearing in at the White House with limited press coverage. His public inauguration will be on the Martin Luther King Jr. holiday, Monday, Jan. 21, since the ceremony is not traditionally held on Sundays.
(Copyright 2012 The Associated Press. All Rights Reserved)


text:
Coping with herbicide-resistant weeds, after decades of the easy, sure control afforded by glyphosate (Roundup), will require a multi-pronged approach, Mississippi growers were told at the 2011 Delta Ag Expo.
As glyphosate-resistant pigweed (Palmer amaranth) spreads in the Mid-South, and resistant Italian ryegrass continues to be documented, producers will need to include alternate chemistries — many of which are decades-old active ingredients — in their weed control programs, a panel of specialists noted.
And after wide-scale adoption of no-till and reduced till practices, in many cases, tillage may also be a necessary component for combating resistant weeds.
"There are many farmers who can tell horror stories of the problems we had with insect resistance to pesticides in the 1970s and 1980s," said Robert Martin, Extension director for Issaquena County, who chaired the forum. "Weed resistance has the potential to be even worse."
Panel participants were Tom Eubank, assistant research/Extension professor at the Delta Research and Extension Center, Stoneville, Miss.; Darrin Dodds, assistant Extension professor of plant and soil sciences at Mississippi State University; Daniel Stephenson, assistant research/Extension professor of weed science at Louisiana State University; Jason Bond, associate research professor of weed science at the Delta Research and Extension Center; and Erick Larson, associate Extension/research professor of plant and soil sciences at Mississippi State University.
Excerpts from their remarks follow:
Eubank: "We've had instances of herbicide resistance since the 1970s. We've had a long run with Roundup: 30-plus years before getting resistance. But we've used this herbicide continuously on millions of acres, in many cases with no-till, and with fewer alternate chemistries. We need to break that cycle.
"This is an issue that's not going away. These resistant weeds are going to continue to spread. We've got to be proactive and timely in using alternate chemistries in conjunction with glyphosate.
Best control obtained when weeds are small
"And it's critical that these alternative chemistries, such as Ignite and Flexstar, be applied to pigweeds when they're 2 inches to 3 inches high, no more than 4 inches. The days are gone when you're going to get control of large pigweeds with any herbicide.
"There is no residual herbicide you can put out in the fall or late winter that will carry over to provide control the following season. It's important that you start with a clean field in the spring — but you may still have to come back later with other materials to control escapes. Metribuzin is still a good burndown material that offers some residual control."
Dodds: "The move by producers to Roundup Ready is like a gerbil on a revolving wheel — it's hard to get off. Once growers got on the wheel, they felt they couldn't afford the cost and/or didn't need tillage and other measures because of the technology fees they were having to pay.
"We've never quit making recommendations for tillage, but production economics and farm size have led many growers away from it. In Mississippi, tillage is still a good option as part of a pigweed and ryegrass control program. It's not a solution in every situation, but we need to keep it in mind as an option.
"We have a limited number of modes of action in herbicides and we need to do all we can to effectively use them and preserve them. In many cases, we're recycling herbicides we've had for 50 years or more. New chemistries don't come along very often — I can count on one hand those I've seen in 10 or 12 years."
Bond: "Unfortunately, we're too often in a reactive mode rather than proactive. Crop rotation, use of alternate chemistries, and tillage are long term, proactive measures in dealing with weed resistance."
'A definite change in the way we farm'
Larson: "This is definitely going to change the way we farm. Crop rotation is one practice that can play a significant role in dealing with resistant weeds.
"A rotation including corn serves as the most effective tool to combat resistant Palmer amaranth and marestail. However, ryegrass is a significant issue for corn production.
"We have documented glyphosate-resistant ryegrass in 12 Delta counties and ALS-resistant ryegrass in 14 counties. This is a very serious issue in corn, and control requires some very aggressive, proactive methods. Ryegrass can be a significant competitor for corn and it needs to be controlled before you ever put the planter in the field. One ryegrass plant per 7 square feet can result in corn yield loss of as much as 27 percent, or 65 bushels per acre, as documented in a Mississippi State University corn verification trial last year.
"This is why we're recommending a more aggressive strategy with burndown with products other than glyphosate and 2,4-D."
[A field day highlighting management programs for glyphosate-resistant Italian ryegrass will be held March 10 at the Capps Center on the campus of the Delta Research and Extension Center at Stoneville. Registration will begin at 7:30 a.m. Plans are to have an actual field tour of research plots, but the program will be moved indoors in the event of inclement weather.]
Dodds: "Glyphosate-resistant pigweed is a major threat to cotton. I saw more in-season tillage and chopping crews last year than in the previous six years combined. We can manage this problem, but growers are going to have to be willing to adapt and to adjust their practices."
Stephenson: "Georgia has good data that turning under pigweed seeds can help control the weed, but if you have to grow a crop on a bed, it can bring the seed right back up.
"We've had only one confirmed case of glyphosate-resistant pigweed in Louisiana, but we have glyphosate-resistant ryegrass in several areas. We also are concerned about resistant water hemp, and we have confirmed resistant johnsongrass, which took massive amounts of herbicide to kill.
Some grower attitudes 'a recipe for disaster'
"Unfortunately, we have some growers who take the attitude, 'I'm going to keep spraying with Roundup until it doesn't work any more.' That's a recipe for disaster.
"Even if you don't have pigweed, but your neighbor does, it's likely going to spread to your fields. The seed will stick to equipment, or to you, like white on rice. A lot of spread is by equipment movement. If you use a custom harvester, make sure they clean their equipment thoroughly before coming to your fields."
Dodds: "There was a grower in the Mississippi hills who bought a sprayer in Arkansas that has a tremendous amount of pigweed seeds in many crevices of the machine. Had he not cleaned it before putting it in his fields, he'd have spread those seeds everywhere. Be extremely careful about buying equipment in areas where there is resistant pigweed — it could be a very costly purchase."
Bond: "Equipment movement is a major way ryegrass is spread. Landplanes do an unbelievably effective job of spreading the seed. It is also easily spread by combines.
"Ryegrass doesn't spread as fast as pigweed and it's usually worse in field margins, or along roads, so you have an opportunity to control it in those areas and limit it spreading to your fields.
"We had many calls last year about fields that were infested with pigweed where they'd never had it before. But it's mind-boggling how big these plants can grow, how much seed a large pigweed plant can produce, and how easily those seeds can spread.
"When I was in graduate school, we grew a pigweed that was 12 feet tall and weighed 45 pounds. In Arkansas, researchers counted 1.7 million seeds on a single plant. Even if you get 96 percent or 97 percent control, with that kind of seed numbers you can get behind the math curve pretty quickly.
Only a matter of time for resistant weeds
"Currently, we have 10 counties in Mississippi, bordering the river, with glyphosate-resistant pigweed. If you don't have them, it's only a matter of time until you will. In 2010, we had some resistant pigweeds in areas near the coast, a long way from the Delta. Most of the coastal counties of Alabama have resistant pigweed, and it's probably only a matter of time until it spreads to the Mississippi hills."
"Residual herbicides now represent a key line of defense against resistant pigweed. How long they will be effective depends on how carefully we manage them.
"Resistance is a moving target and can vary from one year to the next. In some cases, control is textbook; in others, it depends on weather and other factors.
"Remember: residuals need water for activation. If you don't get rain, they won't work. If you look at historical weather data, there usually will be rainfall to activate residual herbicides applied in April. After that, it becomes chancy.
"If you have the ability to irrigate, you can facilitate activation. Overhead irrigation trumps furrow irrigation for herbicide activation."
Dodds: "With residual herbicides, be aware of label restrictions regarding the number of days from application to planting. Counting starts on the date you get the specified amount of rainfall — not the day the material was applied."
Eubank: "Treflan, which goes back many years, is still in our recommendations. But remember, it's a single mode of action — you can't use just that one material — and if you don't incorporate it properly, it's not going to work. "Nothing is going to give you 100 percent control of pigweed, just because of the sheer numbers of seed produced.
Some crop injury may be necessary
"Sencor (mostly generic versions now) is also a good option we haven't used much — not only for pigweed, but for horseweed and ryegrass. . There currently is no pigweed resistance to this material in the Mid-South. Boundary is a combination of Sencor/Dual and is a jam-up combination for these weeds.
"In many situations, some amount of crop injury will be something you will have to live with in order to get control of pigweed."
Bond: "You can expect some injury from a residual herbicide. Some of these materials have been around forever — in the grand scheme of things, they're antiques, but they work the same as they did decades ago, and you're still going to get injury. You've got to seek a balance between some herbicide injury loss and major loss from resistant weed competition."
Dodds: For the last 15 years, we've become accustomed to seeing a robustly-growing cotton crop with little or no injury; however, cotton can sustain some herbicide injury and still produce well."
Eubank: "As we shift more to contact herbicides, it's very important to have adequate coverage. You can't apply these herbicides with AI nozzles, low water volume, and a high ground speed and get the coverage you need.
"If you're going across the field at 20 mph, a lot of your smaller spray particles are being caught up in the vortex of wind and dust behind your sprayer and coverage isn't as effective as it should be. If you miss control the first time around, there's no coming back for a do-over.
"You need an orifice size that will put out the necessary volume of water for thorough coverage. I like 10 gallons minimum, preferably 15 and no more than 10 mph."


text:
Destination Paradise
2 December 2014
Miami, FL - Like birds of migration when the thermometer drops, Audi Melges 20 sailors leave the frozen tundra and begin their annual winter pilgrimage to the sparkling waters of Biscayne Bay, Miami. In its sixth winter series based out of Coconut Grove Yacht Club (CGSC), the class looks to build on experiences from previous years to ensure the racing is world class, and that all owners and sailors have a memorable experience.
With many fleet veterans returning as they have since the very first winter series in 2009/10, there are a few new faces as well. In his first winter series, young owner Drew Wierda on Peshmerga is swapping snow for palm trees and is ready to race in Miami, "I have enjoyed racing the Audi Melges 20 at the 2013 Worlds and 2014 Nationals, but this is my first complete winter series. With the easy logistics, being based out of CGSC and racing against so many great teams and sailors, we can't wait to get racing."
To help close the gap between the front and back of the fleet, Audi Melges 20 leadership has secured multi-world champion, former AC sailor, and successful coach Tom Burnham to serve as the official fleet coach. Having competed in several Audi Melges 20 events, coach Burnham is excited about the opportunity, "As a lifelong sailor I have benefitted greatly from coaching. However not all teams have access to good coaching. The step that the Audi Melges 20 Class is making to provide coaching to the fleet can only improve the competition and camaraderie and foster an environment of learning. I am excited to be a part of that program by coaching the fleet for the December event in Miami."
Coach Burnham will be on the water on Thursday, 10 December, and during the first day of racing on Friday, 11 December to help provide real time feedback, as well as a comprehensive debrief to review themes of the day, and what did and didn't work. For those teams looking for a set of eyes off the boat, this is a great opportunity to learn in a competitive, yet learning environment. Every team is encouraged to partake in the coaching by being prepared for a full day on the water and ready with good questions during the debrief.
Stay tuned for more details, including a full practice agenda will be released prior to the first day of coaching on Thursday.
Being the first event in the winter series, the December event is a delicate balance between shaking the rust off, and having a hot start to ensure solid footing for the remainder of the winter. With multiple champions over the past five seasons, a quick look at the list of registrants reveals a deep field that could see almost any team ascending to the top and raising the overall trophy. It all starts next week.
As with other Audi Melges 20 events around the world, racing updates as they are available will be posted online at the Official Audi Melges 20 Facebook Page. Be sure to also follow the fleet on Instagram, Twitter and YouTube. Tune in for the latest racing information, results, video interviews, and photos. Race reports, press releases and photos will also be available online each day post racing at melges20.com.
1.) Brian Henke, Affordable Mistress
2.) Brian Hill, Atlas
3.) Michael Kiss, Bacio
4.) Rhonda Joyce, Batteries Not Required
5.) John Brown, Blind Squirrel
6.) Rob Wilber, Cinghiale
7.) Tate Russack, Diesel
8.) Mike Keefe, Flannel
9.) Tom Kassberg, Flygfisk
10.) Marc Hollerbach, Fu
11.) Erwan Le Gall, Le Rescator
12.) Travis Weisleder, Lucky Dog/Gill Race Team
13.) Achille Onorato, Mascalzone Latino Jr.
14.) Jason Michas, Midnight Blue
15.) John Taylor, Ninkasi
16.) James Wilson, Oleander
17.) Drew Friedes, Pacific Yankee
18.) Drew Weirda, Peshmerga
19.) Cesar Gomes Neto, Portobello
20.) Paul Reilly, Red Sky
21.) Richard Davies, Section 16
22.) Russell Lucas, Shimmer
23.) Wes Whitmyer, Slingshot
24.) Bo Boje Pedersen, UpUpUp
25.) Paul Currie, Wild Deuces
Official Yachtscoring Event Website
View Full Entry List
Audi Melges 20 on Facebook
Audi Melges 20 on Twitter
Audi Melges 20 on Instagram
Audi Melges 20 on YouTube


text:
How can I make sure my mobo has a PCI Bus Mastering slot? I have PCI slots, but is there any way to distinguish what type they are? I am installing some a wireless adapter card and XP is not detecting it. The forum for the card said to make sure the PCI slot was a "Bus Mastering slot", so that's why I ask.
thnks in advance.


text:
You are here: Home ‹ Board index ‹ Movie Discussion ‹ Upcoming Movies
Used Guys - Jim's to do film with Ben Stiller?
Discuss other upcoming Jim Carrey movies (not confirmed/rumours).
HHHmmmm..........an interesting combination............i LOVED the Cable Guy............but it would be interesting to see Stiller star alongside Jim as oposed to directing him.................
It certainly has possibilities............but lets face it....how many times have you heard he's doing a movie with whoever.............only to find out it was just a rumour.............or shelved............?? ............
so don't hold your breathe folks..............i'm still rooting for the serious thriller...................but that looks even less likely at the moment......... .............
ah well............Fluffy
The storyline sounds really funny.
It just probably would work, I'm laughing at the possibilities.
wow "Used Guys seems the perfect title
Carrey and Stiller will play clones rendered obsolete by superior models whose enhancements include better listening and lovemaking skills. The scorned clones make a run for it, bent on regaining their dignity by searching for a male nirvana known as Mantopia.
I looking forward to it even if Jim doesn't sign on. Plus it sounds like the first buddy movie Jim would be doing (if he hasn't done any in the past.)
I am part of an elite group of people......THE MEN OF JCO.
(Standing member since July 18th, 2005)
I think it's said news. Because Ben Stiller can't make me laugh, he's like ... always the same, time after time. A non-talent if you ask me. But you don't.
re Buddy Movie............DUMB AND DUMBER!!!!!!!
of course i would have like to see him with a British comedian........such as Eddy Izzard...............i think the contrast would be really good...........plus there wouldn't be clash of ego's..........Ben may be inclined to 'direct'...........and i doubt anyone can push Jim about..........lol
my primary concern would be that it doesn't turn into a futuristic Dumb and Dumber.......it would need to have a different slant.....
but i guess they are looking at 2 big names...........but i reckon Jim could pull in the numbers on his own merit without Stiller...........
It all depends on whose baby it is..............if it's Jims then he's got more of a say............if it's Bens then he has...............
lol.........but imagine Eddy Izzard...........an old clone...but somethings gone askew they forgot to clone out perversions ......lol..... ....and he starts off by wearing ladies knickers under his jeans......and he might moan about his VPL, or his knickers riding up his bum............then as the film progresses he moves onto stockings, suspenders, a bra....then ladies clothes.............
but i'ts done dead-pan............Jim could walk in on him fastening his bra......or he could be fixing his stockings................lol............
But Jim just gawks....he doesn't make any references to it ........lol.................until right at the end......when he says something like 'come here you'.....lol........and chases Eddy around the bed...........lol........then cut!!...............
lol...............well, it's an idea..............lol.........but i won't give up the day job.....not yet anyhow............lol
Last edited by fluffy on Thu Sep 01, 2005 4:35 pm, edited 4 times in total.
I read this yesterday at a spanish website and thought "Wow! Jim Carrey AND Ben Stiller starring in the same movie!". I totally love the idea. The plot sounds completely crazy, but I think that's good in this case. I think if these two guys do it, it can be hilarious.
Looking forward!
Who is online
Users browsing this forum: No registered users and 3 guests